206 related articles for article (PubMed ID: 29676642)
1. Immunomethylomics: A Novel Cancer Risk Prediction Tool.
Kelsey KT; Wiencke JK
Ann Am Thorac Soc; 2018 Apr; 15(Suppl 2):S76-S80. PubMed ID: 29676642
[TBL] [Abstract][Full Text] [Related]
2. Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival.
Wiencke JK; Koestler DC; Salas LA; Wiemels JL; Roy RP; Hansen HM; Rice T; McCoy LS; Bracci PM; Molinaro AM; Kelsey KT; Wrensch MR; Christensen BC
Clin Epigenetics; 2017; 9():10. PubMed ID: 28184256
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
4. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.
Koestler DC; Usset J; Christensen BC; Marsit CJ; Karagas MR; Kelsey KT; Wiencke JK
Cancer Epidemiol Biomarkers Prev; 2017 Mar; 26(3):328-338. PubMed ID: 27965295
[No Abstract] [Full Text] [Related]
6.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic epigenetic biomarkers in cancer.
Costa-Pinheiro P; Montezuma D; Henrique R; Jerónimo C
Epigenomics; 2015; 7(6):1003-15. PubMed ID: 26479312
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
[TBL] [Abstract][Full Text] [Related]
9. Use of DNA methylation for cancer detection: promises and challenges.
Zhu J; Yao X
Int J Biochem Cell Biol; 2009 Jan; 41(1):147-54. PubMed ID: 18834953
[TBL] [Abstract][Full Text] [Related]
10. Blood-derived DNA methylation markers of cancer risk.
Marsit C; Christensen B
Adv Exp Med Biol; 2013; 754():233-52. PubMed ID: 22956505
[TBL] [Abstract][Full Text] [Related]
11. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
12. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
13. Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
Rieke DT; Ochsenreither S; Klinghammer K; Seiwert TY; Klauschen F; Tinhofer I; Keilholz U
Oncotarget; 2016 Nov; 7(46):75379-75393. PubMed ID: 27683114
[TBL] [Abstract][Full Text] [Related]
14. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
15. Conservation of immune gene signatures in solid tumors and prognostic implications.
Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
[TBL] [Abstract][Full Text] [Related]
16. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D
Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105
[TBL] [Abstract][Full Text] [Related]
17. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.
Marzese DM; Hoon DS
Expert Rev Mol Diagn; 2015 May; 15(5):647-64. PubMed ID: 25797072
[TBL] [Abstract][Full Text] [Related]
18. Survival differences of CIMP subtypes integrated with CNA information in human breast cancer.
Wang H; Yan W; Zhang S; Gu Y; Wang Y; Wei Y; Liu H; Wang F; Wu Q; Zhang Y
Oncotarget; 2017 Jul; 8(30):48807-48819. PubMed ID: 28415743
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
20. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors.
Marsit CJ; Houseman EA; Christensen BC; Eddy K; Bueno R; Sugarbaker DJ; Nelson HH; Karagas MR; Kelsey KT
Cancer Res; 2006 Nov; 66(21):10621-9. PubMed ID: 17079487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
